Int J Syst Bacteriol 1997, 47:385–393.PubMedCrossRef 5. Suh SO, Blackwell M: Three new beetle-associated yeast species Cytoskeletal Signaling inhibitor in the Pichia guilliermondii clade. FEMS Yeast Res 2004, 5:87–95.PubMedCrossRef 6. Vaughan-Martini A, Kurtzman CP, Meyer SA, O’Neill EB: Two new species in the Pichia guilliermondii clade: Pichia caribbica sp. nov., the ascosporic state of Candida fermentati

, and Candida carpophila comb. nov. FEMS Yeast Res 2005, 5:463–469.PubMedCrossRef 7. Kam AP, Xu J: Diversity of commensal yeasts within and among healthy hosts. Diagn Microbiol Infect Dis 2002, 43:19–28.PubMedCrossRef 8. Xu J, Mitchell TG: Geographical differences in human oral yeast flora. Clin Infect Dis 2003, 36:221–224.PubMedCrossRef 9. Krcmery V, Barnes AJ: Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal

resistance. J Hosp Infect 2002, 50:243–260.PubMedCrossRef 10. Savini V, Catavitello C, Onofrillo D, Masciarelli G, Astolfi D, Balbinot A, Febbo F, D’Amario C, D’Antonio D: What do we know about Candida guilliermondii ? A voyage throughout past and current literature about this emerging yeast. Mycoses 2011, 54:434–441.PubMedCrossRef 11. Papon N, Savini V, Lanoue A, Simkin AJ, Creche J, Giglioli-Guivarc’h N, Clastre M, Courdavault V, Sibirny AA: Candida guilliermondii STAT inhibitor : biotechnological applications, perspectives for biological control, emerging clinical importance and recent advances in genetics. Curr Genet 2013. (in press) (doi:10.1007/s00294–013–0391–0) 12. Miceli MH, Diaz JA, Lee SA: Emerging opportunistic yeast infections. Lancet Infect Dis 2011, 11:142–151.PubMedCrossRef

13. Neppelenbroek K, Seo R, Urban V, Silva S, Dovigo L, Jorge J, Campanha N: Identification of Candida species in the clinical laboratory: a review of conventional, commercial, and molecular techniques. Oral Dis 2013. (in press) (doi:10.1111/odi.12123) 14. Sandven P: Epidemiology of candidemia. Rev Iberoam Micol 2000, 17:73–81.PubMed 15. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA: Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole Monoiodotyrosine and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010, 48:1366–1377.PubMedCentralPubMedCrossRef 16. Chen CY, Huang SY, Tang JL, Tsay W, Yao M, Ko BS, Chou WC, Tien HF, Hsueh PR: Clinical features of patients with infections caused by Candida guilliermondii and Candida fermentati and antifungal Veliparib mouse susceptibility of the isolates at a medical centre in Taiwan, 2001–10. J Antimicrob Chemother 2013. (in press) (doi:10.1093/jac/dkt214) 17. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ: Identification and susceptibility profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. J Clin Microbiol 2009, 47:242–244.PubMedCentralPubMedCrossRef 18.